Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia

Devimistat is a TCA cycle inhibitor. A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response rates. Here we report the results of a single arm phase II study (NCT02484391). The primary ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Rebecca, Miller, Lance D., Isom, Scott, Chou, Jeff W., Pladna, Kristin M., Schramm, Nathaniel J., Ellis, Leslie R., Howard, Dianna S., Bhave, Rupali R., Manuel, Megan, Dralle, Sarah, Lyerly, Susan, Powell, Bayard L., Pardee, Timothy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967916/
https://www.ncbi.nlm.nih.gov/pubmed/35354808
http://dx.doi.org/10.1038/s41467-022-29039-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967916/
https://www.ncbi.nlm.nih.gov/pubmed/35354808
http://dx.doi.org/10.1038/s41467-022-29039-4

Ejemplares similares